ecrin-mdr-crcClinical2007Metastatic Colorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2040127Spain5IrinotecanPanitumumab2nd-line TherapyECRIN MDRCompletedfalsePanitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRCThe purpose of this study is to assess the objective response rate (ORR) when panitumumab is administered in combination with irinotecan as 2nd-line therapy in subjects with previously treated metastatic colorectal cancer (mCRC).2007-05-152040127NCT00475293